Trial Profile
A Randomized, Single-Blind, Placebo-Controlled Crossover, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of UROCORTIN II in Healthy Subjects and in Patients with moderate Congestive Heart Failure (CHF).
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Jun 2016
Price :
$35
*
At a glance
- Drugs Urocortin 2 (Primary)
- Indications Heart failure
- Focus Adverse reactions
- 15 Nov 2011 ANZCTR says trial is ph I. But MR says several phase I and two ph II trials in CHF have been completed. It appears that this must be one of the ph II trials (changed to ph I/II)
- 02 Sep 2011 New trial record